Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | MDH1 | P40925 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.44 |
| ▸ | HTR3B | O95264 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.44 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.44 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL8709610 | 0.99 | EPHX2 (0.50) | EPHX2HTR2CADRA2AADORA3CHRM1 | |
| SCHEMBL14218010 | 0.86 | EPHX2 (0.47) | EPHX2HTR2CHTR3EHTR3BHTR1A | |
| SCHEMBL8916991 | 0.85 | EPHX2 (0.48) | EPHX2HTR2CHTR3EHTR3BHTR1A | |
| SCHEMBL8707832 | 0.83 | ADRA2A (0.54) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| SCHEMBL9036740 | 0.83 | EPHX2 (0.55) | EPHX2HTR2CHTR3EHTR3BHTR1A | |
| Piperazine SCHEMBL8711683 | 0.83 | ADRA2A (0.53) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| SCHEMBL12139321 | 0.82 | MAPK1 (0.52) | ADRA2AADORA3CHRM1MAOATBXA2R | |
| SCHEMBL8916808 | 0.82 | HTR2C (0.38) | HTR2CPLD1 | |
| SCHEMBL8792881 | 0.81 | EPHX2 (0.56) | EPHX2HTR2CHTR3EHTR3BHTR1A | |
| SCHEMBL11886200 | 0.80 | GSK3B (0.42) | ADRA2AADORA3CHRM1MAOATBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025133260-A1 | INHIBITORS OF PLASMODIA REMODELING ENZYMES | UNIVERSITÄT REGENSBURG, IN VERTRETUNG DES FREISTAATES BAYERN (DE) | 2025-06-26 | — | — | WO | claimed |
| CN-114605303-A | Synthesis method of delavirdine and intermediate thereof | 武汉工程大学 | 2022-06-10 | — | — | CN | claimed |
| CN-102633778-B | Synthesis method of anti-AIDS medicine delavirdine | NANJING ACESYS PHARMACEUTICAL TECHNOLOGY CO LTD | 2014-04-16 | — | — | CN | claimed |
| CN-102675284-A | Synthesis method of delavirdine | ENSI WANG | 2012-09-19 | — | — | CN | claimed |
| CN-102633778-A | Synthesis method of anti-AIDS medicine delavirdine | NANJING ACESYS PHARMACEUTICAL TECHNOLOGY CO LTD | 2012-08-15 | — | — | CN | claimed |
| EP-0729948-B1 | The production of 3-alkylamino-2-piperazinylpyridines | UPJOHN CO (US) | 1999-09-01 | — | — | EP | claimed |
| EP-0690848-B1 | PIPERAZINYLPYRIDINYL WATER CLATHRATES | UPJOHN CO (US) | 1998-01-21 | — | — | EP | claimed |
| US-5686610-A | Pyridyl piperazine compound | PHARMACIA & UPJOHN COMPANY (US) | 1997-11-11 | — | — | US | claimed |
| EP-0507318-B1 | Benzothiazole derivative | EISAI CO LTD (JP) | 1997-09-10 | — | — | EP | claimed |
| EP-0729948-A1 | The production of 3-alkylamino-2-piperazinylpyridines | THE UPJOHN COMPANY (US) | 1996-09-04 | — | — | EP | claimed |
| CN-122059926-A | Heterocyclic degradation determinants for target protein degradation | C4医药公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2025133260-A1 | INHIBITORS OF PLASMODIA REMODELING ENZYMES | UNIVERSITÄT REGENSBURG, IN VERTRETUNG DES FREISTAATES BAYERN (DE) | 2025-06-26 | — | — | WO | disclosed |
| US-20250121069-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| CN-119325475-A | Bicyclic substituted glutarimide cereblon binders | C4医药公司 | 2025-01-17 | — | — | CN | disclosed |
| EP-0690848-A1 | PIPERAZINYLPYRIDINYL WATER CLATHRATES | PHARMACIA & UPJOHN COMPANY (US) | 1996-01-10 | — | — | EP | disclosed |
| WO-1994022836-A2 | PIPERAZINYLPYRIDINYL WATER CLATHRATES | THE UPJOHN COMPANY (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1993001181-A1 | SUBSTITUTED INDOLES AS ANTI-AIDS PHARMACEUTICALS | THE UPJOHN COMPANY (US) | 1993-01-21 | — | — | WO | disclosed |
| EP-0507861-A1 | DIAROMATIC SUBSTITUTED ANTI-AIDS COMPOUNDS. | UPJOHN CO (US) | 1992-10-14 | — | — | EP | disclosed |
| WO-1991009849-A1 | DIAROMATIC SUBSTITUTED ANTI-AIDS COMPOUNDS | THE UPJOHN COMPANY (US) | 1991-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250121069-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | EPHX2 3227/4885HTR2C 897/4885ADRA2A 3240/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | EPHX2 2048/4885HTR2C 4008/4885ADRA2A 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.